CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression

被引:83
|
作者
Reynes, J
Portales, P
Segondy, M
Baillat, V
André, P
Avinens, O
Picot, MC
Clot, J
Eliaou, JF
Corbeau, P
机构
[1] Hop St Eloi, Immunol Lab, F-34295 Montpellier 5, France
[2] Hop St Eloi, Virol Lab, F-34295 Montpellier, France
[3] Hop Gui De Chauliac, Serv Malad Infect & Trop, Montpellier, France
[4] Hop Arnaud Villeneuve, Dept Med Informat, Montpellier, France
[5] Inst Genet Humaine, Montpellier, France
关键词
AIDS/HIV; CCR5; CD4 cell slope; chemokine receptor; long-term non-progressor; prognostic factor; T lymphocytes;
D O I
10.1097/00002030-200109070-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective and design: We have recently shown that the number of CCR5 molecules at the surface of peripheral blood CD4 T cells (CCR5 density) correlates with the viral RNA plasma level in HIV-1-infected individuals. As viral load is a strong predictor of outcome in HIV infection, the present study examines the correlation between CCR5 density and HIV-1 disease progression. Methods: Using a quantitative flow cytometry assay, we measured CCR5 density in HIV-1-infected adults and control healthy volunteers. The CCR5 genotype (presence of a Delta 32 allele) was also determined. Results: CCR5 density was stable over time on non-activated, HLA-DR(-)CD4 T cells of infected individuals. In a study cohort of 25 patients, asymptomtic and non-treated, we observed a correlation between CCR5 density on HLA-DR-CD4 T cells and the CD4 T cell slope (P = 0.026), which was independent of the presence or absence of the Delta 32CCR5 deletion. In particular, slow progressors expressed lower CCR5 densities than non-slow progressors (P = 0.004) and non-infected control subjects (P = 0.002). Conclusion: These results are compatible with the hypothesis that CCR5 density, which is a key factor of HIV-1 infectability, determines in-vivo HIV production, and thereby the rate of CD4 cell decline. Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1627 / 1634
页数:8
相关论文
共 50 条
  • [1] CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis
    Anjali Joshi
    Erin B. Punke
    Melina Sedano
    Bethany Beauchamp
    Rima Patel
    Cassady Hossenlopp
    Ogechika K. Alozie
    Jayanta Gupta
    Debabrata Mukherjee
    Himanshu Garg
    Scientific Reports, 7
  • [2] CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis
    Joshi, Anjali
    Punke, Erin B.
    Sedano, Melina
    Beauchamp, Bethany
    Patel, Rima
    Hossenlopp, Cassady
    Alozie, Ogechika K.
    Gupta, Jayanta
    Mukherjee, Debabrata
    Garg, Himanshu
    SCIENTIFIC REPORTS, 2017, 7
  • [3] CCR5 antagonist-resistant HIV-1 entry kinetics as a function of CD4 and CCR5 surface expression
    Putcharoen, O.
    Lee, S-H
    Henrich, T. J.
    Vanichanan, J.
    Kuritzkes, D. R.
    Tsibris, A. M. N.
    ANTIVIRAL THERAPY, 2011, 16 : A64 - A64
  • [4] Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry
    Nahabedian, John
    Sharma, Amit
    Kaczmarek, Maryska E.
    Wilkerson, Greg K.
    Sawyer, Sara L.
    Overbaugh, Julie
    VIROLOGY, 2017, 512 : 180 - 186
  • [5] Low CD4+ T-Cell surface CCR5 density as a cause of resistance to in vivo HIV-1 infection
    Reyues, J
    Baillat, V
    Portales, P
    Clot, J
    Corbeau, P
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (01) : 114 - 116
  • [6] CCR5, vertical transmission of HIV-1, and disease progression
    Bailey, AJ
    Newell, ML
    De Rossi, A
    Giaquinto, C
    Iasci, A
    Ravizza, M
    Garcia-Rodriguez, MC
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (02): : 211 - 212
  • [7] CCR5 promoter polymorphism and HIV-1 disease progression
    McDermott, DH
    Zimmerman, PA
    Guignard, F
    Kleeberger, CA
    Leitman, SF
    Murphy, PM
    LANCET, 1998, 352 (9131): : 866 - 870
  • [8] Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression
    Butticaz, C
    Ciuffi, A
    Muñoz, MM
    Thomas, J
    Bridge, A
    Pebernard, S
    Iggo, R
    Meylan, P
    Telenti, A
    ANTIVIRAL THERAPY, 2003, 8 (05) : 373 - 377
  • [9] CCR5 cell surface density and HIV-1 envelope sequences govern antiretroviral potency of CCR5 antagonists
    Miller, MD
    Lineberger, JE
    Dornadula, G
    Danzeisen, RC
    Blau, CR
    Danovich, RM
    Miller, MA
    Finke, PE
    Oates, BD
    Caldwell, CG
    Chen, P
    Meurer, LC
    Mills, SG
    Springer, MS
    Petropoulos, CJ
    Whitcomb, J
    Huang, W
    Fransen, S
    Simon, AJ
    Hazuda, DJ
    ANTIVIRAL THERAPY, 2003, 8 (03) : U66 - U67
  • [10] CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Heredia, Alonso
    Gilliam, Bruce
    DeVico, Anthony
    Le, Nhut
    Bamba, Douty
    Flinko, Robin
    Lewis, George
    Gallo, Robert C.
    Redfield, Robert R.
    AIDS, 2007, 21 (10) : 1317 - 1322